It is worth noting that, in addition to improved CBF, enhancement of the ACE2-Ang 1–7/1–9-MasR/AT2R pathway likely also protects against post-stroke injury through other pathways, including decreased inflammation and further thrombotic complications and, thus, represents a potential therapy with pleiotropic effects. This evidence concerns the gene MAS1L and stroke disorder.